11/19
05:41 pm
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $80.00 price target on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $80.00 price target on the stock.
11/18
07:12 am
rytm
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide [Yahoo! Finance]
11/18
07:00 am
rytm
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
Medium
Report
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
11/13
06:36 pm
rytm
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology [Yahoo! Finance]
11/13
06:30 pm
rytm
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
Low
Report
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
11/13
04:12 pm
rytm
Rhythm Pharmaceuticals Announces New Employment Inducement Grants [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Announces New Employment Inducement Grants [Yahoo! Finance]
11/13
04:01 pm
rytm
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Low
Report
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11/7
08:36 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at HC Wainwright from $64.00 to $69.00. They now have a "buy" rating on the stock.
High
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at HC Wainwright from $64.00 to $69.00. They now have a "buy" rating on the stock.
11/7
08:25 am
rytm
Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/7
02:43 am
rytm
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/6
01:10 pm
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at TD Cowen from $55.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at TD Cowen from $55.00 to $65.00. They now have a "buy" rating on the stock.
11/6
01:10 pm
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $77.00 to $80.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $77.00 to $80.00. They now have a "buy" rating on the stock.
11/6
08:07 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $55.00 to $64.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $55.00 to $64.00. They now have a "buy" rating on the stock.
11/6
08:00 am
rytm
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
High
Report
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
11/5
04:01 pm
rytm
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
High
Report
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
11/4
04:19 pm
rytm
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 [Yahoo! Finance]
11/4
04:01 pm
rytm
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
Medium
Report
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
10/30
08:00 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $55.00 price target on the stock.
Medium
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $55.00 price target on the stock.
10/25
08:37 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
10/24
06:00 am
rytm
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
Low
Report
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
10/23
08:00 am
rytm
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
Low
Report
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
10/21
08:07 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $70.00 price target on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $70.00 price target on the stock.
10/14
02:38 pm
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Bank of America Co. from $48.00 to $52.00. They now have a "neutral" rating on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Bank of America Co. from $48.00 to $52.00. They now have a "neutral" rating on the stock.
10/8
04:01 pm
rytm
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Low
Report
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
10/7
08:17 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.